These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M Front Immunol; 2021; 12():745320. PubMed ID: 34712233 [TBL] [Abstract][Full Text] [Related]
4. Management of cytokine release syndrome related to CAR-T cell therapy. Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160 [TBL] [Abstract][Full Text] [Related]
5. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy]. Zhou LL; Ye SG; Li P; Tang XC; Liang AB Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526 [No Abstract] [Full Text] [Related]
6. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia. Wang X; Zhang B; Zhang Q; Zhou H; Sun Q; Zhou Y; Li T; Zhou D; Shen Z; Zhang J; Li P; Liang A; Zhou K; Han L; Hu Y; Yang Y; Cao J; Li Z; Xu K; Sang W Cancer; 2024 Aug; 130(15):2660-2669. PubMed ID: 38578977 [TBL] [Abstract][Full Text] [Related]
7. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871 [TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973 [TBL] [Abstract][Full Text] [Related]
9. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Furqan F; Bhatlapenumarthi V; Dhakal B; Fenske TS; Farrukh F; Longo W; Akhtar O; D'Souza A; Pasquini M; Guru Murthy GS; Runaas L; Abedin S; Mohan M; Shah NN; Hamadani M Blood Adv; 2024 Aug; 8(16):4320-4329. PubMed ID: 38889435 [TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697 [TBL] [Abstract][Full Text] [Related]
11. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Perl M; Herfeld K; Harrer DC; Höpting M; Schweiger M; Sterz U; Knödler L; Heimerl S; Hansmann L; Herr W; Poeck H; Wolff D; Edinger M; Hart C; Fante MA Haematologica; 2024 Sep; 109(9):2969-2977. PubMed ID: 38546698 [TBL] [Abstract][Full Text] [Related]
12. An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study. Qi K; Yan Z; Cheng H; Chen W; Wang Y; Wang X; Cao J; Zhang H; Sang W; Zhu F; Sun H; Li D; Wu Q; Qiao J; Fu C; Zeng L; Li Z; Zheng J; Xu K Front Oncol; 2021; 11():691064. PubMed ID: 34195092 [TBL] [Abstract][Full Text] [Related]
13. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K Front Immunol; 2021; 12():611366. PubMed ID: 33708205 [TBL] [Abstract][Full Text] [Related]
14. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Kotch C; Barrett D; Teachey DT Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357 [No Abstract] [Full Text] [Related]
17. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353 [TBL] [Abstract][Full Text] [Related]
18. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
19. [The occurrence of cytokine release syndrome and its impact on the prognosis of patients with relapsed and refractory multiple myeloma following chimeric antigen receptor T-cell therapy]. Nian L; Jie XX; Zhang LW; Yan ZL; Qi KM; Zhang HX; Xu KL; Cheng H; Li ZY Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(33):3148-3153. PubMed ID: 39168846 [No Abstract] [Full Text] [Related]